ClinicalTrials.gg

Program

azetukalner

Also written as “XEN1101”, “Azetukalner” and “XEN1101 10 mg”.

Its studies are mostly in Depressive Disorder, Major · Epilepsies, Partial · Seizures · Bipolar Disorder · Epilepsy, led by Xenon Pharmaceuticals.

Furthest: phase 3, since Nov 6, 202212 company-led studies, 9 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xenon Pharmaceuticals129 open or runningphase 3since Nov 6, 2022Jan 2, 2019Jan 2027phase 3 · NCT06922110

Also a collaborator on its studies: novotech-health-holdings-pte-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 2, 2019First study: phase 2 study in Epilepsies, PartialFirst studyNCT03796962 · 325 enrolled · United States, Canada, Georgia and more
  2. Jun 27, 2021Phase 1 study in Healthy VolunteersNCT04952467 · 6 enrolled · United Kingdom
  3. May 11, 2022Phase 2 study in Depressive Disorder, MajorNCT05376150 · 168 enrolled · United States
  4. Nov 6, 2022Phase 3 study in SeizuresNCT05614063 · 380 enrolled · United States, Argentina, Australia and more
  5. Dec 19, 2022Phase 3 study in EpilepsyNCT05667142 · 160 planned · United States, Argentina, Australia and more
  6. Jan 13, 20232 phase 3 studiesNCT05718817, NCT05716100
  7. Jan 9, 2025Phase 3 study in Depressive Disorder, MajorNCT06775379 · 450 enrolled · United States
  8. Mar 20, 2025Phase 3 study in Depressive Disorder, MajorNCT06922110 · 460 enrolled · United States, Finland, Poland
  9. Jul 14, 2025Phase 3 study in Depressive Disorder, MajorNCT07076407 · 450 enrolled · United States, Finland, Germany and more
  10. Sep 8, 2025Phase 3 study in Bipolar DisorderNCT07172516 · 400 enrolled · United States, Bulgaria, Germany and more
  11. Oct 14, 2025Phase 3 study in Bipolar DisorderNCT07217860 · 400 enrolled · United States
  12. Oct 8, 2026Primary completion moved from 2026-10 to 2028-01Date moved laterphase 3 · +15 months · NCT05716100
  13. Oct 13, 2026Primary completion moved from 2026-08 to 2026-10Date moved laterphase 3 · +2 months · NCT06775379

Ahead

  1. Jan 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06922110
  2. Apr 2027Primary completion: phase 3 study in EpilepsyNCT05667142
  3. May 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07076407
  4. Jan 2028Primary completion: phase 3 study in SeizuresNCT05716100

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07217860Bipolar Disorder · United States3Active, not recruitingJun 2029400
NCT07172516Bipolar Disorder · United States, Bulgaria, Germany and more3Active, not recruitingJun 2028400
NCT07076407Depressive Disorder, Major · United States, Finland, Germany and more3Active, not recruitingMay 2027450
NCT06922110Depressive Disorder, Major · United States, Finland, Poland3Active, not recruitingJan 2027460
NCT06775379Depressive Disorder, Major · United States3Active, not recruitingOct 2026450
NCT05716100Seizures · United States, Argentina, Australia and more3RecruitingJan 2028360
NCT05718817Epilepsies, Partial · United States, Argentina, Australia and more3By invitationApr 2033880
NCT05667142Epilepsy · United States, Argentina, Australia and more3RecruitingApr 2027160
NCT05614063Seizures · United States, Argentina, Australia and more3CompletedJan 12, 2026380
NCT05376150Depressive Disorder, Major · United States2CompletedSep 18, 2023168
NCT04952467Healthy Volunteers · United Kingdom1CompletedOct 4, 20216
NCT03796962Epilepsies, Partial · United States, Canada, Georgia and more2Active, not recruitingSep 2, 2021325

How it is read

Names in the registry

  • “XEN1101”, 5 entries
  • “Azetukalner”, 5 entries
  • “XEN1101 10 mg”, 1 entry
  • “XEN1101 20 mg”, 1 entry
  • “14C-XEN1101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.